Brian O'MAhony
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brian O'MAhony has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Andrew Harkin
Trinity College Institute of Neuroscience
2 shared publicationsColm McDonald
University of Galway
2 shared publicationsNíall Lally
University of Galway
2 shared publications- Radoslaw Kaczmarek
Indiana University School of Medicine, Herman B Wells Center for Pediatric Research, Indianapolis, USA
2 shared publications Adele Morrin
Milltown Mental Health Services Dublin Ireland
1 shared publication- Alok Srivastava
Haematology Research Unit, St. John's Research Institute and St. John's Medical College Hospital Bengaluru India
1 shared publication
Latest Publications
- Open Access
- 19 October 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-6
Clinical characteristics of HHC-associated psychosis: an exploratory retrospective inpatient cohort study
Objectives: To describe the demographic, clinical, and treatment characteristics of individuals admitted with hexahydrocannabinol (HHC)-associated psychosis and compare with cannabis-associated psychosis. Methods: A retrospective chart review was undertaken of all admissions to the Adult Acute Mental Health Unit at University Hospital Galway, Ireland, between 1 May 2023 and 31 July 2025, with psychosis and documented HHC or cannabis use in the seven days preceding admission. Demographic, clinical, and treatment variables were compared across three groups: HHC-only, cannabis-only, and combined HHC + cannabis associated psychosis. Group differences were examined using ANOVA for continuous variables and Fisher’s exact tests for categorical variables, with repeated-measures ANOVA used to examine antipsychotic dosing. Analyses were exploratory in nature. Results: Thirty-three individuals (79% male) met inclusion criteria. All HHC-related cases occurred in a first episode of psychosis. Affective symptoms were more frequent in the HHC-only group (89%) than in the cannabis-only (54%) and combined HHC + cannabis groups (27%) (p = 0.024). Formal thought disorder appeared more common in HHC-exposed groups (80%) compared with cannabis-only presentations (38%), reaching statistical significance in an exploratory comparison between cannabis-only and combined HHC-exposed groups (p = 0.027). Urine toxicology screening for THC metabolites, length of stay and maximum antipsychotic dose were similar across groups. Conclusion: In this cohort, HHC-associated psychosis was associated with higher rates of affective symptoms and formal thought disorder than cannabis-related presentations, despite otherwise similar clinical features. Findings are hypothesis-generating, given the exploratory analyses, small sample and uncorrected multiple testing. They suggest a potential role for novel cannabinoid screening to support earlier identification and management.
- 19 October 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-6
Open AccessClinical characteristics of HHC-associated psychosis: an exploratory retrospective inpatient cohort study
Objectives: To describe the demographic, clinical, and treatment characteristics of individuals admitted with hexahydrocannabinol (HHC)-associated psychosis and compare with cannabis-associated psychosis. Methods: A retrospective chart review was undertaken of all admissions to the Adult Acute Mental Health Unit at University Hospital Galway, Ireland, between 1 May 2023 and 31 July 2025, with psychosis and documented HHC or cannabis use in the seven days preceding admission. Demographic, clinical, and treatment variables were compared across three groups: HHC-only, cannabis-only, and combined HHC + cannabis associated psychosis. Group differences were examined using ANOVA for continuous variables and Fisher’s exact tests for categorical variables, with repeated-measures ANOVA used to examine antipsychotic dosing. Analyses were exploratory in nature. Results: Thirty-three individuals (79% male) met inclusion criteria. All HHC-related cases occurred in a first episode of psychosis. Affective symptoms were more frequent in the HHC-only group (89%) than in the cannabis-only (54%) and combined HHC + cannabis groups (27%) (p = 0.024). Formal thought disorder appeared more common in HHC-exposed groups (80%) compared with cannabis-only presentations (38%), reaching statistical significance in an exploratory comparison between cannabis-only and combined HHC-exposed groups (p = 0.027). Urine toxicology screening for THC metabolites, length of stay and maximum antipsychotic dose were similar across groups. Conclusion: In this cohort, HHC-associated psychosis was associated with higher rates of affective symptoms and formal thought disorder than cannabis-related presentations, despite otherwise similar clinical features. Findings are hypothesis-generating, given the exploratory analyses, small sample and uncorrected multiple testing. They suggest a potential role for novel cannabinoid screening to support earlier identification and management.
- Open Access
- 4 September 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-3
Implementing psychedelic-assisted therapy in Ireland: perspectives from a national stakeholder survey
- 4 September 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1-3
Open AccessImplementing psychedelic-assisted therapy in Ireland: perspectives from a national stakeholder survey
- Open Access
- 28 July 2026
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 20 (8) , e70226
Longitudinal Dietary Intake of Young People With a First Episode of Psychosis From the Time of Presentation to Six Months Follow‐Up
Background: Antipsychotic medications stimulate appetite and weight gain, contributing to high obesity rates in people with psychotic disorders. It is unknown if these dietary effects habituate over time. This study aimed to determine the dietary intake of young people with a first‐episode psychosis at the time of presentation and at three‐ and six‐months of follow‐up. Methods: We assessed dietary patterns at baseline, 3 months, and 6 months in participants diagnosed with first‐episode psychosis who had minimal prior antipsychotic exposure. We analysed data from the PHAstER randomised‐controlled trial, assessing changes in food consumption and Australian Dietary Guideline compliance using signed‐rank tests with corrections for multiple testing. Results: Of the 77 PHAstER study participants, 70 participants (91%) provided dietary data at baseline and 46 (60%) at 3 and 6 months. Dietary intake patterns and compliance with dietary guidelines remained consistent across all three timepoints. At baseline, few met recommended intake of three major food groups: vegetables (13%), dairy (20%) and fruit (24%). 64% of participants had a high intake of discretionary food (food high in saturated fat/sugars). At baseline, but not at three‐ or six‐months, higher education levels were associated with healthier dietary patterns. Conclusion: Participants consistently reported unhealthy diets that did not adhere to guidelines, with no significant change over 6 months. This study reinforces the inequity of dietary health in people with psychosis, particularly those with lower levels of education. Dietary advice and support represent interventions with high marginal gain in this cohort, and should be part of routine clinical care.
- 28 July 2026
- Published by Wiley in Early Intervention in Psychiatry
- Vol. 20 (8) , e70226
Open AccessLongitudinal Dietary Intake of Young People With a First Episode of Psychosis From the Time of Presentation to Six Months Follow‐Up
Background: Antipsychotic medications stimulate appetite and weight gain, contributing to high obesity rates in people with psychotic disorders. It is unknown if these dietary effects habituate over time. This study aimed to determine the dietary intake of young people with a first‐episode psychosis at the time of presentation and at three‐ and six‐months of follow‐up. Methods: We assessed dietary patterns at baseline, 3 months, and 6 months in participants diagnosed with first‐episode psychosis who had minimal prior antipsychotic exposure. We analysed data from the PHAstER randomised‐controlled trial, assessing changes in food consumption and Australian Dietary Guideline compliance using signed‐rank tests with corrections for multiple testing. Results: Of the 77 PHAstER study participants, 70 participants (91%) provided dietary data at baseline and 46 (60%) at 3 and 6 months. Dietary intake patterns and compliance with dietary guidelines remained consistent across all three timepoints. At baseline, few met recommended intake of three major food groups: vegetables (13%), dairy (20%) and fruit (24%). 64% of participants had a high intake of discretionary food (food high in saturated fat/sugars). At baseline, but not at three‐ or six‐months, higher education levels were associated with healthier dietary patterns. Conclusion: Participants consistently reported unhealthy diets that did not adhere to guidelines, with no significant change over 6 months. This study reinforces the inequity of dietary health in people with psychosis, particularly those with lower levels of education. Dietary advice and support represent interventions with high marginal gain in this cohort, and should be part of routine clinical care.
- Open Access
- 16 July 2026
- Published by BMJ in BMJ Mental Health
- Vol. 29 (1) , e302720
Weight loss prior to diagnosis of first-episode psychosis predicts subsequent weight gain: a retrospective cohort study of the UK Clinical Practice Research Datalink (CPRD) primary care database
Background: Post-psychosis weight gain is commonly rapid, yet prediagnosis weight changes are under-researched. The untreated phase of first-episode psychosis (FEP) can be characterised by behaviour which could lead to weight loss, triggering physiological adaptations which prime the body to regain weight. Objective: We aimed to investigate the prevalence and extent of weight loss prior to diagnosis of FEP, and to investigate its impact on subsequent weight gain. Methods: We used Clinical Practice Research Datalink primary care data, supplemented with linked hospital episode statistics, ethnicity and deprivation data to estimate pre-FEP weight loss prevalence. We then used multiple linear regression to assess its association with subsequent weight change, while adjusting for relevant confounders. Findings: Primary analysis included 369 individuals with adequate data. 53% of individuals experienced weight loss before FEP. Using percentage weight change as an outcome, individuals with pre-FEP weight loss gained weight post-FEP at over twice the rate of those without prior loss (8.93% (95% CI 6.90% to 10.96%) bodyweight per year vs 4.07% per year (95% CI 1.90% to 6.24%); p=0.005). Each 1% of pre-FEP weight loss predicted 0.41% (95% CI 0.23% to 0.59%) additional annual weight gain (p=0.004), most pronounced within 6 months and independent of antipsychotic treatment selection. Using kilogram per year as an outcome, average gain (6.49 kg (95% CI 5.28 kg to 7.70 kg)) exceeded average prior loss (4.83 kg (95% CI 4.00 kg to 5.66 kg)) by 1 year. Findings were robust across sensitivity analyses. Conclusions: Pre-FEP weight loss is common and predicts rapid post-diagnosis gain. While all patients were expected to gain weight, those with pre-FEP weight loss gained double the weight of those who had not lost weight. Clinical implications: Clinicians treating individuals with FEP should enquire about weight loss in the pretreatment period, which predicts extra weight gain in the initial period following diagnosis. This could inform early intervention to avoid consequences of short-term weight gain.
- 16 July 2026
- Published by BMJ in BMJ Mental Health
- Vol. 29 (1) , e302720
Open AccessWeight loss prior to diagnosis of first-episode psychosis predicts subsequent weight gain: a retrospective cohort study of the UK Clinical Practice Research Datalink (CPRD) primary care database
Background: Post-psychosis weight gain is commonly rapid, yet prediagnosis weight changes are under-researched. The untreated phase of first-episode psychosis (FEP) can be characterised by behaviour which could lead to weight loss, triggering physiological adaptations which prime the body to regain weight. Objective: We aimed to investigate the prevalence and extent of weight loss prior to diagnosis of FEP, and to investigate its impact on subsequent weight gain. Methods: We used Clinical Practice Research Datalink primary care data, supplemented with linked hospital episode statistics, ethnicity and deprivation data to estimate pre-FEP weight loss prevalence. We then used multiple linear regression to assess its association with subsequent weight change, while adjusting for relevant confounders. Findings: Primary analysis included 369 individuals with adequate data. 53% of individuals experienced weight loss before FEP. Using percentage weight change as an outcome, individuals with pre-FEP weight loss gained weight post-FEP at over twice the rate of those without prior loss (8.93% (95% CI 6.90% to 10.96%) bodyweight per year vs 4.07% per year (95% CI 1.90% to 6.24%); p=0.005). Each 1% of pre-FEP weight loss predicted 0.41% (95% CI 0.23% to 0.59%) additional annual weight gain (p=0.004), most pronounced within 6 months and independent of antipsychotic treatment selection. Using kilogram per year as an outcome, average gain (6.49 kg (95% CI 5.28 kg to 7.70 kg)) exceeded average prior loss (4.83 kg (95% CI 4.00 kg to 5.66 kg)) by 1 year. Findings were robust across sensitivity analyses. Conclusions: Pre-FEP weight loss is common and predicts rapid post-diagnosis gain. While all patients were expected to gain weight, those with pre-FEP weight loss gained double the weight of those who had not lost weight. Clinical implications: Clinicians treating individuals with FEP should enquire about weight loss in the pretreatment period, which predicts extra weight gain in the initial period following diagnosis. This could inform early intervention to avoid consequences of short-term weight gain.
- Open Access
- 30 April 2026
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 9, 47
Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome (START GAAIMS): A Feasibility Study Protocol
Background Individuals with psychotic disorders face a 20-year mortality gap compared to the general population, largely driven by cardiovascular disease and metabolic syndrome. Antipsychotic medications, while essential, exacerbate this risk through rapid weight gain and metabolic dysregulation, particularly in the first three months of treatment. Resistance training improves body composition and metabolic health, particularly glucose regulation. Its effects on muscle strength and hypertrophy are enhanced by a caloric surplus that, in its absence, would otherwise lead to accumulation of adipose tissue. Its feasibility and efficacy in drug-naïve or minimally treated First-Episode Psychosis (FEP) patients has not been previously explored. Methods The START GAAIMS study is a multicentre, two-arm, crossover, randomised controlled feasibility trial. Forty adults (18–65 years) with FEP and < 4 weeks of antipsychotic exposure will be recruited from services in Dublin and Cork. Participants will be randomised (1:1) to an Intervention Group (12-week supervised RT programme + Treatment as Usual [TAU]) or a Control Group (TAU only). After 12 weeks, the control group will crossover to receive the intervention. Outcome Measures The primary outcome is the feasibility of the trial design (recruitment, retention, adherence) and a preliminary estimate of the effect size for change in body fat percentage at 12 weeks. Secondary outcomes include muscular power, metabolic biomarkers (glucose, lipids, inflammatory markers), and psychiatric symptoms (BPRS). Discussion This study will determine preliminary measures of the effects of resistance training on body composition in people with FEP starting antipsychotic medication, as well as its feasibility and acceptability in this cohort. Findings will inform the design of a definitive RCT to establish RT as a standard co-treatment for metabolic health in early psychosis.
- 30 April 2026
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 9, 47
Open AccessStrategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome (START GAAIMS): A Feasibility Study Protocol
Background Individuals with psychotic disorders face a 20-year mortality gap compared to the general population, largely driven by cardiovascular disease and metabolic syndrome. Antipsychotic medications, while essential, exacerbate this risk through rapid weight gain and metabolic dysregulation, particularly in the first three months of treatment. Resistance training improves body composition and metabolic health, particularly glucose regulation. Its effects on muscle strength and hypertrophy are enhanced by a caloric surplus that, in its absence, would otherwise lead to accumulation of adipose tissue. Its feasibility and efficacy in drug-naïve or minimally treated First-Episode Psychosis (FEP) patients has not been previously explored. Methods The START GAAIMS study is a multicentre, two-arm, crossover, randomised controlled feasibility trial. Forty adults (18–65 years) with FEP and < 4 weeks of antipsychotic exposure will be recruited from services in Dublin and Cork. Participants will be randomised (1:1) to an Intervention Group (12-week supervised RT programme + Treatment as Usual [TAU]) or a Control Group (TAU only). After 12 weeks, the control group will crossover to receive the intervention. Outcome Measures The primary outcome is the feasibility of the trial design (recruitment, retention, adherence) and a preliminary estimate of the effect size for change in body fat percentage at 12 weeks. Secondary outcomes include muscular power, metabolic biomarkers (glucose, lipids, inflammatory markers), and psychiatric symptoms (BPRS). Discussion This study will determine preliminary measures of the effects of resistance training on body composition in people with FEP starting antipsychotic medication, as well as its feasibility and acceptability in this cohort. Findings will inform the design of a definitive RCT to establish RT as a standard co-treatment for metabolic health in early psychosis.
- Open Access
- 23 March 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 687-702
Trip killers: Addressing a critical knowledge gap in psychedelic research
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a “bad trip.” Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.
- 23 March 2026
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 687-702
Open AccessTrip killers: Addressing a critical knowledge gap in psychedelic research
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a “bad trip.” Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.
- 4 January 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1
Free will from both sides: a review of “Free Agents” by Kevin Mitchell, and “Determined” by Robert Sapolsky, Princeton University Press, 2023, ISBN-13: 978-069122621; Penguin Press 2023, ISBN-13: 978-0-525-56097-5
Free will from both sides: a review of “Free Agents” by Kevin Mitchell, and “Determined” by Robert Sapolsky, Princeton University Press, 2023, ISBN-13: 978-069122621; Penguin Press 2023, ISBN-13: 978-0-525-56097-5
- 4 January 2026
- Published by Cambridge University Press (CUP) in Irish Journal of Psychological Medicine
- p. 1
Free will from both sides: a review of “Free Agents” by Kevin Mitchell, and “Determined” by Robert Sapolsky, Princeton University Press, 2023, ISBN-13: 978-069122621; Penguin Press 2023, ISBN-13: 978-0-525-56097-5
Free will from both sides: a review of “Free Agents” by Kevin Mitchell, and “Determined” by Robert Sapolsky, Princeton University Press, 2023, ISBN-13: 978-069122621; Penguin Press 2023, ISBN-13: 978-0-525-56097-5
- Open Access
- 4 November 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (1) , 55-61
Quantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation study
Hemophilia A is an inherited bleeding disorder caused by a deficiency of clotting factor VIII (FVIII), leading to joint bleeding and arthropathy. While prophylactic FVIII therapy reduces bleeding, evidence suggests maintaining higher FVIII levels (FL) may better protect joint health, particularly in physically active individuals and those with joint damage. However, data on optimal FLs required to prevent joint deterioration and complications remains limited. This study utilized the Sheffield Elicitation Framework (SHELF) methodology to elicit expert opinions on optimal FLs for patient-centric and clinical outcomes. Five European hemophilia experts participated in virtual workshops, providing probability-based estimates of FLs required to prevent bleed-related hospitalizations, orthopedic procedures, target joint incidence, and support physical activity without additional infusions or joint damage. Experts consistently recommended higher FLs for individuals with joint damage than for those without. Optimal average FLs ranged from 24% to 51%, exceeding traditionally recommended prophylactic trough levels (3-5%). Considerable uncertainty was noted around FLs for physical activity, reflecting the complexity of individualized care. Standard prophylaxis regimens may not provide sufficient protection for all patients, particularly those with joint damage. A personalized treatment approach, targeting higher FLs when necessary, may be critical for optimizing outcomes.
- 4 November 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (1) , 55-61
Open AccessQuantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation study
Hemophilia A is an inherited bleeding disorder caused by a deficiency of clotting factor VIII (FVIII), leading to joint bleeding and arthropathy. While prophylactic FVIII therapy reduces bleeding, evidence suggests maintaining higher FVIII levels (FL) may better protect joint health, particularly in physically active individuals and those with joint damage. However, data on optimal FLs required to prevent joint deterioration and complications remains limited. This study utilized the Sheffield Elicitation Framework (SHELF) methodology to elicit expert opinions on optimal FLs for patient-centric and clinical outcomes. Five European hemophilia experts participated in virtual workshops, providing probability-based estimates of FLs required to prevent bleed-related hospitalizations, orthopedic procedures, target joint incidence, and support physical activity without additional infusions or joint damage. Experts consistently recommended higher FLs for individuals with joint damage than for those without. Optimal average FLs ranged from 24% to 51%, exceeding traditionally recommended prophylactic trough levels (3-5%). Considerable uncertainty was noted around FLs for physical activity, reflecting the complexity of individualized care. Standard prophylaxis regimens may not provide sufficient protection for all patients, particularly those with joint damage. A personalized treatment approach, targeting higher FLs when necessary, may be critical for optimizing outcomes.
- Open Access
- 10 July 2025
- Published by Royal College of Psychiatrists in Bjpsych Bulletin
- Vol. 50 (2) , 132-137
Novel substance, same old problems: admissions of psychosis precipitated by hexahydrocannabinol, a widely available semi-synthetic cannabinoid
Aims and method: To investigate the impact of the widespread availability and use of the semi-synthetic cannabinoid hexahydrocannabinol (HHC) on hospital admissions owing to psychosis. Medical records of patients admitted for psychotic illness to University Hospital Galway were examined to assess HHC or other illicit drug use before admission. Results: Of the 214 total admissions for psychotic illness, 28 admissions (13.1%) were preceded by use of HHC, nine of whom used only HHC. Sixteen (34%) admissions of first-episode psychosis were preceded by HHC use, with seven of these using only HHC. Clinical implications: Clinicians should explicitly enquire about the use of HHC in patients presenting with first-episode and relapse of psychotic illness. Sufficient evidence has now accumulated from research of a link between HHC and psychosis. Such psychoses appear to be more prominent in young people with early-phase psychosis, and highlights the need for authorities to change legislation to avoid further harm.
- 10 July 2025
- Published by Royal College of Psychiatrists in Bjpsych Bulletin
- Vol. 50 (2) , 132-137
Open AccessNovel substance, same old problems: admissions of psychosis precipitated by hexahydrocannabinol, a widely available semi-synthetic cannabinoid
Aims and method: To investigate the impact of the widespread availability and use of the semi-synthetic cannabinoid hexahydrocannabinol (HHC) on hospital admissions owing to psychosis. Medical records of patients admitted for psychotic illness to University Hospital Galway were examined to assess HHC or other illicit drug use before admission. Results: Of the 214 total admissions for psychotic illness, 28 admissions (13.1%) were preceded by use of HHC, nine of whom used only HHC. Sixteen (34%) admissions of first-episode psychosis were preceded by HHC use, with seven of these using only HHC. Clinical implications: Clinicians should explicitly enquire about the use of HHC in patients presenting with first-episode and relapse of psychotic illness. Sufficient evidence has now accumulated from research of a link between HHC and psychosis. Such psychoses appear to be more prominent in young people with early-phase psychosis, and highlights the need for authorities to change legislation to avoid further harm.
- Open Access
- 19 February 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
A plain language summary of the phase 3 explorer7 study of concizumab prophylaxis for people with hemophilia with inhibitors
- 19 February 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
Open AccessA plain language summary of the phase 3 explorer7 study of concizumab prophylaxis for people with hemophilia with inhibitors